BriefCase-Quantification vs Tempus ECG-AF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (BriefCase-Quantification) is designed for radiologists and vascular surgeons, providing automated abdominal aortic diameter measurements from CT scans to aid in structural assessment. Tool B (Tempus ECG-AF) targets cardiologists, geriatricians, and internal medicine specialists, analyzing 12-lead ECGs to predict the risk of new-onset atrial fibrillation. While both are FDA-cleared AI tools within cardiology, they address different clinical problems using distinct diagnostic modalities.
Choose BriefCase-Quantification if…
Choose BriefCase-Quantification if your radiology department requires automated, precise measurements of abdominal aortic diameter from CT scans. This tool is ideal for streamlining workflows and assisting radiologists in clinical decision-making related to vascular health assessments, particularly for conditions like aneurysms.
View BriefCase-Quantification →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your cardiology or internal medicine practice aims to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year. This AI-based algorithm provides valuable risk stratification from standard 12-lead ECGs, enabling earlier follow-up and potential intervention for at-risk individuals.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | BriefCase-Quantification | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact for pricing | Contact vendor |
| Deployment | Cloud-based | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | BriefCase-Quantification | Tempus ECG-AF |
|---|---|---|
| Tool Name | BriefCase-Quantification | Tempus ECG-AF |
| Company | Aidoc Medical | Tempus AI, Inc. |
| Description | FDA-cleared AI tool for radiologists, providing automated abdominal aortic diameter measurements from CT scans to assist clinical decision-making and streamline workflows. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Key Features | Automated abdominal aortic diameter measurement; Radiological image management and processing; Integration with image review software; Cloud-based deployment; Assists medical specialists with quantitative measurements; Part of Aidoc's aiOSu2122 enterprise AI platform; Supports streamlined clinical workflows | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI |
| Specialties | Cardiology, Radiology, Vascular Surgery | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring BriefCase-Quantification and Tempus ECG-AF.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Aidoc's BriefCase-Quantification is an FDA-cleared AI tool for radiologists that provides automated abdominal aortic diameter measurements from CT scans to assist clinical decision-making and streamline workflows. Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
BriefCase-Quantification is indicated for use in the analysis of contrast-enhanced CT exams that include the abdominal aorta in adults or transitional adolescents aged 18 and older. Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
BriefCase-Quantification processes and analyzes CT scans to provide automated abdominal aortic diameter measurements. Tempus ECG-AF analyzes 12-lead ECG recordings to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months.
BriefCase-Quantification is designed for specialties such as Cardiology, Radiology, and Vascular Surgery. Tempus ECG-AF is relevant for Cardiology, Geriatrics, and Internal Medicine.